Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts (Q82359485)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1 reference

Gregg R Masters

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Marc A Berger

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Earl F Albone

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

24 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

462-467

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Immunocytochemical and serological expression of CA 125: a clinicopathological study of 40 malignant ovarian epithelial tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Tissue and serum CA125 expression in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Serum tumor markers in the management of ovarian, endometrial and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Lung tumour markers in oncology practice: a study of TPA and CA125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Elevated CA125 in breast cancer--A sign of advanced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

CA 125 in benign gynecological conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

The follow-up of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Primary ovarian cancer chemotherapy: current standards of care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

In vitro studies of Taxol as a radiation sensitizer in human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Comparison of the biodistribution and the efficacy of monoclonal antibody labeled with either 131I or 186Re in human ovarian cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

Taxol sensitizes human ovarian cancer cells to radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.004

10.1016/J.YGYNO.2005.12.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16434088%20AND%20SRC:MED&resulttype=core&format=json